CAL-101: Phase II started

Calistoga began an open-label, U.S. Phase II trial to evaluate twice-daily 150 mg CAL-101 plus 375 mg/m 2 weekly rituximab in 60 elderly patients with previously untreated CLL and SLL. Biogen Idec In...